Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes

Novo Nordisk A/S3,637 enrolled

Overview

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.

Study Type

OBSERVATIONAL

Enrollment

3,637

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

insulin detemirDRUG

Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Type 1 diabetes * Type 2 diabetes * Candidates of use of a basal insulin as part of their diabetes regimen Exclusion Criteria: * Unwilling to adhere to therapy or follow up * Pregnancy

Locations (1)

Novo Nordisk Investigational Site

Moscow, Russia

Outcomes

Primary Outcomes

HbA1C

Time frame: after 12 weeks

Secondary Outcomes

Safety

Time frame: during treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.